Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2026-02-25 Director's Dealing
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. It details the sale of shares by an executive (Kim Soo-hyun) of Celltrion. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider transactions by company management.
2026-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Commission and the Korea Exchange. This is a standard regulatory filing in South Korea used to disclose insider shareholdings and transactions by company directors or major shareholders. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure for company insiders (directors/executives) to report their shareholdings and any changes in their ownership (insider trading). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-02-25 Korean
소송등의판결ㆍ결정
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure from Celltrion regarding a court decision on a lawsuit ('소송등의판결ㆍ결정'). It details the dismissal of a request for an extraordinary general meeting of shareholders. Since this document pertains to a legal proceeding and a court ruling, it falls under the 'Legal Proceedings Report' category.
2026-02-19 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (Article 13-3). It is a specific, structured regulatory filing required by Korean law for companies like Celltrion. Since it does not fit into categories like financial reports, earnings releases, or shareholder communications, it falls under the general regulatory filing category.
2026-02-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집결의) issued by Celltrion. It details the date, location, and specific agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and amendments to the articles of incorporation. This type of filing is a standard proxy solicitation document used to inform shareholders of meeting details and request their participation/votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.